Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.39 |
| ▸ | OXTR | P30559 | 1/20 | 0.34 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2474689 | 0.92 | GPR119 (0.39) | GPR119HRH3TACR1 | |
| SCHEMBL2473876 | 0.89 | GPR119 (0.47) | GPR119OXTRAVPR1AHRH3PDE4A | |
| SCHEMBL2336519 | 0.88 | DDB1 (0.35) | GPR119OXTRAVPR1APDE4APDE4B | |
| SCHEMBL2475380 | 0.87 | GPR119 (0.35) | GPR119OXTRAVPR1AHRH3PDE4A | |
| SCHEMBL2469674 | 0.86 | PDE4A (0.34) | GPR119OXTRAVPR1APDE4APDE4B | |
| SCHEMBL2336887 | 0.85 | PDE4B (0.36) | GPR119OXTRAVPR1APDE4APDE4B | |
| SCHEMBL2472676 | 0.85 | GPR119 (0.36) | GPR119OXTRAVPR1APDE4APDE4B | |
| SCHEMBL2340272 | 0.85 | DDB1 (0.35) | GPR119OXTRAVPR1APDE4APDE4B | |
| SCHEMBL2337016 | 0.85 | DDB1 (0.35) | GPR119OXTRAVPR1APDE4APDE4B | |
| SCHEMBL2469541 | 0.84 | GPR119 (0.34) | GPR119OXTRAVPR1APDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3035939-A1 | V1A ANTAGONISTS TO TREAT PHASE SHIFT SLEEP DISORDERS | F. Hoffmann-La Roche AG (CH) | 2016-06-29 | — | — | EP | claimed |
| WO-2015024819-A1 | V1A ANTAGONISTS TO TREAT PHASE SHIFT SLEEP DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-26 | — | — | WO | claimed |
| EP-2370441-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN VIA RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-10-05 | — | — | EP | claimed |
| WO-2010060836-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN VIA RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-03 | — | — | WO | claimed |
| EP-3035939-A1 | V1A ANTAGONISTS TO TREAT PHASE SHIFT SLEEP DISORDERS | F. Hoffmann-La Roche AG (CH) | 2016-06-29 | — | — | EP | disclosed |
| WO-2015024819-A1 | V1A ANTAGONISTS TO TREAT PHASE SHIFT SLEEP DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-26 | — | — | WO | disclosed |
| EP-2370441-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN VIA RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-10-05 | — | — | EP | disclosed |
| WO-2010060836-A1 | ARYLCYCLOHEXYLETHERS OF DIHYDROTETRAAZABENZOAZULENES FOR USE AS VASOPRESSIN VIA RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-03 | — | — | WO | disclosed |